PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för saroglitazar. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

9 hits

Bibliografisk träff 2016-06-23

Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode.

Ghoghari A, Dash R, Bhatt C, Singh K, Jha A, Patel H, Gupta R, Kansagra K, Srinivas NR.

Biomed Chromatogr · validation study; journal article · DOI 10.1002/bmc.3760

Bibliografisk träff 2015-12-01

Unique Interaction of Saroglitazar with Insulin.

Sethi BK, Nagesh VS, Kelwade J, Vaseem A.

J Assoc Physicians India · letter; case reports

Bibliografisk träff 2015-05-04

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.

Jain MR, Giri SR, Trivedi C, Bhoi B, Rath A, Vanage G, Vyas P, Ranvir R, Patel PR.

Pharmacol Res Perspect · research-article; journal article · DOI 10.1002/prp2.136

Bibliografisk träff 2015-04-15

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence.

Sosale A, Saboo B, Sosale B.

Diabetes Metab Syndr Obes · review-article; review; journal article · DOI 10.2147/dmso.s49592

Bibliografisk träff 2015-03-01

Saroglitazar for the treatment of dyslipidemia in diabetic patients.

Joshi SR.

Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2015.1009894

Bibliografisk träff 2015-01-01

From 'Make in India' to 'Made in India': the saroglitazar story.

Ramakrishnan S.

Indian Heart J · comment; editorial · DOI 10.1016/j.ihj.2015.02.014

Bibliografisk träff 2015-01-01

Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.

Shetty SR, Kumar S, Mathur RP, Sharma KH, Jaiswal AD.

Indian Heart J · research-article; multicenter study; journal article; observational study · DOI 10.1016/j.ihj.2015.02.007

Bibliografisk träff 2014-02-01

The first approved agent in the Glitazar's Class: Saroglitazar.

Agrawal R.

Curr Drug Targets · journal article · DOI 10.2174/13894501113149990199

Bibliografisk träff 2013-11-01

Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.

Jani RH, Kansagra K, Jain MR, Patel H.

Clin Drug Investig · research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s40261-013-0128-3